Watch: the CureRays® explainer series
Prefer to read? The full guide below is complete on its own, with tables you can revisit any time.
What is vulvovaginal melanoma?
Vulvovaginal melanoma is a melanoma — a cancer of the pigment-producing cells called melanocytes — that develops on the vulva or inside the vagina. Unlike the common skin melanomas linked to sun exposure, this is a 'mucosal' melanoma that arises on moist internal surfaces, so sunlight is not the cause and it often carries different gene changes (such as KIT or NRAS rather than the BRAF mutations typical of skin melanoma). It usually affects older women and may appear as a dark or sometimes colorless spot, a lump, bleeding, itching, or discharge — symptoms easily mistaken for something benign, which is one reason it is often found late. Because these tumors sit in a hidden area and tend to spread early, they are challenging to treat, but a combination of surgery, radiation, and immune-based therapy now offers better control than in the past.
The main types
Doctors group vulvovaginal melanoma by where it starts and how it behaves:
| Type | What it means, simply |
|---|---|
| Vulvar melanoma | Arises on the external genital skin and mucosa of the vulva; more accessible to surgery than vaginal melanoma. |
| Vaginal melanoma | Arises on the lining inside the vagina; harder to remove completely and generally carries a poorer outlook. |
| Mucosal melanoma (shared biology) | Both belong to the family of mucosal melanomas, which differ genetically from sun-related skin melanoma and respond differently to targeted drugs. |
Staging, in plain terms
There is no single official staging system for vulvovaginal melanoma. Doctors adapt the framework used for skin melanoma and clinical extent of disease: localized to the vulva or vagina, spread to nearby (groin or pelvic) lymph nodes, or spread to distant organs. Tumor thickness and whether it can be completely removed strongly influence treatment and outlook.
| Adapted clinical staging (no dedicated FIGO/TNM) | What it generally means |
|---|---|
| Localized (stage I) | Confined to the vulva or vagina with no detected spread. Surgery offers the best chance of control. |
| Regional nodes (stage II) | Spread to nearby lymph nodes in the groin or pelvis. Treated with surgery plus radiation and/or immunotherapy. |
| Distant spread (stage III/IV) | Spread to distant organs such as the lungs, liver, or brain. Systemic immunotherapy becomes the backbone of treatment. |
The standard of care
Vulvovaginal Melanoma is almost always treated by a team that may include a surgeon, a medical oncologist, and a radiation oncologist, combining therapies for the best result. The usual building blocks are:
Surgery (primary local treatment)
Removing the tumor with a margin of normal tissue is the main local treatment. Surgeons aim to balance complete removal against preserving function, often choosing less radical operations than in the past because wider surgery has not clearly improved survival.
Radiation therapy
Radiation after surgery substantially lowers the chance of the cancer returning locally, and it can serve as the main local treatment when surgery would be too disfiguring or the tumor cannot be removed.
Immunotherapy (the modern backbone)
Immune checkpoint inhibitors such as nivolumab, pembrolizumab, and ipilimumab activate the immune system against melanoma and are central for advanced disease and increasingly combined with surgery or radiation.
Targeted therapy in selected tumors
Because some vulvovaginal melanomas carry KIT mutations, targeted KIT-inhibitor drugs are an option for those specific tumors.
How radiation treatment works
Radiation damages the DNA inside melanoma cells so they can no longer divide. Melanoma tends to respond best to large doses per session, so techniques like SBRT and brachytherapy — which concentrate a high dose precisely on the target — are particularly valuable here. After surgery, radiation to the tumor bed and nearby lymph nodes markedly lowers the chance the cancer returns in the pelvis. Radiation can also stimulate the immune system, which is why it is increasingly combined with immunotherapy. It is painless, delivered over a small number of sessions, and leaves no radioactivity behind.
The main ways radiation is delivered for vulvovaginal melanoma:
Adjuvant external-beam radiation (IMRT/IGRT)
Image-guided radiation to the tumor bed and at-risk nodes after surgery dramatically reduces local recurrence, shaping the dose around the bladder, rectum, and bowel.
Stereotactic body radiation (SBRT)
Delivers a few high, focused doses; melanoma responds well to the large per-session doses SBRT provides, useful for the primary tumor or an isolated metastasis, and it pairs well with immunotherapy.
Brachytherapy
Radiation placed directly at the vaginal surface delivers a concentrated dose to the tumor or surgical bed while sparing surrounding organs.
Latest studies shaping care
Care keeps improving — often toward getting the same excellent results with less burden on patients. A few developments:
Adjuvant radiation cuts local failure: In vaginal melanoma, surgery alone left about 45% with local recurrence, whereas adding adjuvant radiation reduced local failure to roughly 7% — establishing radiation as a key part of local control even though distant spread remains the main challenge.[1]
PMC4899413 / vaginal melanoma outcomes series
Combined immunotherapy and radiation: Reports of concurrent immune checkpoint therapy with radiation (including SBRT) for lower genital-tract mucosal melanoma describe strong local responses, including complete responses, supporting combined treatment for this aggressive disease.[2]
PMC8654617
Pembrolizumab plus hypofractionated radiation (NCT04318717): An active trial pairs the immunotherapy pembrolizumab with short-course radiation specifically for mucosal melanoma, testing whether the combination improves outcomes for cancers like vulvovaginal melanoma that respond poorly to either alone.[3]
ClinicalTrials.gov NCT04318717
Common questions
I avoided the sun — how did I get melanoma? Vulvovaginal melanoma is a mucosal melanoma that arises on internal surfaces, not sun-exposed skin, so sunlight is not the cause. It develops from pigment cells in the vulva or vagina and tends to carry different gene changes than ordinary skin melanoma — which also affects which drugs work best.
Will surgery be very extensive? Not necessarily. Surgeons now often favor removing the tumor with a clear margin while preserving as much function as possible, because very radical surgery has not been shown to improve survival. Radiation after surgery is frequently added to control the area, and immunotherapy treats the body as a whole.
How does immunotherapy help? Immune checkpoint inhibitors release the brakes on your immune system so it can attack melanoma cells, and they are central to treating advanced disease. They are increasingly combined with radiation, which can both control the tumor locally and help stimulate the immune response.
References
Numbered sources for the studies cited above. Links open the primary publication on PubMed or the publisher’s site.
- PMC4899413 / vaginal melanoma outcomes series (no indexed identifier — see your care team) ↩
- PMC8654617 (no indexed identifier — see your care team) ↩
- ClinicalTrials.gov NCT04318717 (no indexed identifier — see your care team) ↩